The main obstacle to successful organ transplantation today is the recipient's recognition of the implanted cells as foreign, and his reaction to this intrusion through cellular and/or humoral mechanisms normally triggered by infectious microorganisms (1). The tempo and intensity of this immunological response are conditioned significantly by the degree of genetic or antigenic disparity existing between donor and recipient (2). This consideration has stimulated an intensive search for techniques capable of selecting optimally compatible donor-recipient pairs for organ transplantation. Such techniques include in vivo tests performed with skin allografts (third man test) or with lymphocytes (normal lymphocyte transfer test) obtained from prospective donors and recipients, and in vitro cellular (mixed lymphocyte cultures) and serological (leukocyte group antigens) reactions (3). The latter effort, largely stimulated by the classical studies of Gorer and Snell and their associates (4-7), has provided cogent evidence for the existence in different mammalian species of a major system of histocompatibility whose components are amenable to serological analysis and definition. Such histocompatibility systems include the murine H-2 system (6), HL-A in man (8), Ag-B (9) or RhH-1 (10) in rats, GPL-A in guinea pigs (11), PL-A in pigs (12), ChL-A in chimpanzees (13), and RhL-A in rhesus monkeys (14).

Another important approach to the transplantation problem has been concerned with the search for specific immunological techniques capable of inducing allograft tolerance without interference with the remainder of the host's immunological defenses (1). Historically, this endeavor began with the studies of Medawar and his associates in 1951 (15), and led to Billingham, Brent, and Medawar's (16) definition of immunological tolerance as a weakening or suppression of allograft responsiveness through exposure of the host to specific antigenic stimulation before the development of immunological competence. Since then, this concept has been broadened considerably, and the dividing lines between classical immunological tolerance and
serologically mediated allograft enhancement (17, 18) have become increasingly tenuous (15). It has also been reported that treatment of adult animals with transplantation antigens after the development of immunological competence may decrease allograft reactivity in the recipients (19-22). As noted in the classical monograph of van Bekkum and de Vries (23), the combined use of total body irradiation and bone marrow transplantation in rodents has provided an alternative and uniquely important approach to this problem.

In their attempt to extend the latter experimental approach to the canine species, Ferrebee and Thomas and their associates established a selectively bred colony of beagles at the Mary Imogene Bassett Hospital (24), and observed that only an occasional dog exposed to supralethal total body irradiation and given a bone marrow transplant from a randomly selected donor survived this treatment without untoward effects (25). Such survivors were also unresponsive to skin allografts obtained from their donor of marrow (25). The one long-term renal allograft of Mannick et al. (26) and the one long-term lung allograft of Blumenstock et al. (27) performed under similar experimental conditions suggested that these radiation chimeras might also be unresponsive to other tissues obtained from the donor of marrow. The principal obstacle to more extensive study of this experimental model was the unavailability of methods of donor selection capable of providing a regularly reproducible take and a long-term survival of a bone marrow transplant in the dog. Most bone marrow transplants either failed to take or caused fatal secondary graft-versus-host (GVH) disease in the recipients (28). Some means of prospective selection of compatible donor-recipient pairs thus appeared to be essential to permit progress of this endeavor.

In further studies of this question, Kasakura, Thomas, and Ferrebee (29), Puza et al. (30), Rubinstein and Ferrebee (31), Cleton, van Es, Ponsen, and van Rood (32), Cohen and Kozari (33), and Epstein, Storb, Ragde, and Thomas (34) observed that immunization of dogs, and particularly of littermates (34), with buffy coat cells resulted in the appearance of leukocyte group-specific isoantibodies in the recipients. In an extension of the elegant studies of Epstein et al. (34), Rubinstein and associates (35), and Mollen et al. (36) produced a battery of typing sera capable of detecting 10 different leukocyte antigen specificities (or sets of specificities) in the Cooperstown colony of beagles. Transplantation studies performed on the basis of donor-recipient compatibility for these antigens in the Cooperstown Colony have shown that allografts of skin (36), kidney (37), heart (38), lung (39), and liver (40) are accorded prolonged survivals in compatible animals. Conversely, allografts transplanted across major leukocyte group incompatibilities are rejected rapidly. This result, taken together with evidence that such leukocyte antigens behave as Mendelian autosomal dominants in the Cooperstown Colony (41), suggested that these leukocyte antigens were components of a single major system of histocompatibility, for which the term DL-A was proposed (37). Bos et al. (42), Westbroek et al. (43), Templeton and Thomas (44), and Vriesendorp et al. (45) have recently provided additional evidence to support the existence of this major histocompatibility locus in the canine species.

Recent studies of the segregation of the components of the DL-A system in 679 offspring of 141 consecutive matings in the Cooperstown Colony have identified 23

---

1 Abbreviations used in this paper: DIH, distemper-infectious hepatitis vaccine; GVH, graft-versus host; MST, mean survival time.
different DL-A haplotypes (i.e., specificities, or sets of specificities, determined by the DL-A region of one chromosome) in this colony (46), and have demonstrated that all currently known DL-A antigen(s) are regularly transmitted en bloc from parents to offspring, with no evidence of independent segregation. These studies have also resulted in the definition of the DL-A genotypes of 1302 offspring of 517 matings in the Cooperstown Colony (46). Preliminary studies (47, 48) have raised the possibility that the application of such genotypic criteria of donor-recipient DL-A identity might considerably improve the results of bone marrow transplantation in the canine species (49).

This report describes the long-term survival of 17 consecutive irradiated recipients of bone marrow allografts obtained from prospectively selected genotypically DL-A-identical donors, 11 littermate and 6 nonlittermate. The recipients are thus far surviving without evidence of GVH disease for periods of 211–649 days, and are unresponsive to kidney and skin allografts obtained from their donor of marrow. They have, however, rejected DL-A-incompatible skin allografts obtained from other donors at the same rate as untreated dogs. The results suggest that total body irradiation and transplantation of bone marrow from a genotypically DL-A-identical donor induces in the recipient a state of unresponsiveness to other tissue allografts from the same donor. The immunological specificity of this tolerant state is demonstrated by the ability of the recipients to reject promptly allografts obtained from other donors.

Materials and Methods

Selection of Donors and Recipients.—Adult male and female beagles of the Cooperstown Colony weighing 18–25 lb. were used throughout this study. Donor-recipient pairs for bone marrow transplantation were selected on the basis of genotypic evidence of DL-A identity. The DL-A genotypes of all of the animals used were obtained as a result of the earlier definition of the DL-A haplotypes and of their segregation in each succeeding generation of the various different lines of selectively bred animals maintained in the colony (46). Deduction of each genotype was confirmed by serological testing with a standard battery of lymphocytotoxic DL-A antisera. The method of preparation of these antisera and the typing technique used have been described previously (34–37). 12 different DL-A specificities (or sets of specificities) were detected by this method, including b, c, d, e, f, g, h, k, l, m, n, and o. Erythrocyte group antigens A, C, and D were detected with the typing sera and by the technique of Swisher and Young (50). Coefficients of relationship of each donor and recipient and of their respective parents were determined in each experiment.

Method of Total Body Irradiation and Bone Marrow Transplantation.—The method of supralethal total body irradiation has been described in detail previously (51). Each recipient was exposed to 1200–1400 R of continuous irradiation from two opposing 60Co sources, at a source-to-target distance of 2–2.5 m, with an exposure rate of 3–4 R/min. 12–18 hr later, a bone marrow transplant obtained from a prospectively selected genotypically DL-A-identical donor was performed by a modification of the standard technique (52), consisting of the intravenous infusion of a suspension of 3–3.5 × 10^8 nucleated bone marrow cells obtained by needle aspiration of the long bones and sternum of the donor (52). Leukocyte and platelet counts were performed three times weekly for the first 21 days after irradiation and at weekly intervals thereafter. Return of leukocyte and platelet levels to normal values after treatment and the absence of GVH disease constituted evidence of successful take and proliferation of
the bone marrow transplant (53). Persistence of chimerism was confirmed at regular intervals by the continuing presence of donor erythrocyte group antigens in the recipient, and by the appearance of the sex characteristics of donor cells in the recipient's peripheral leukocytes (54).

**Method of Study of Serum Antibody Responses.**—Each animal received an intramuscular injection of 1 ml of distemper and infectious hepatitis (DIH) vaccine (prepared by Dr. James A. Baker, Veterinary Virus Research Institute, Cornell University, Ithaca, N. Y.) at the age of 3 months (55). Serum antibody levels were determined immediately before irradiation. The animals received additional booster immunizations of 1 ml of vaccine before kidney transplantation and at various intervals thereafter. Anti-distemper and anti-infectious hepatitis virus antibody determinations were performed in Dr. Baker's laboratory by standard viral neutralization tests (56, 57).

**Methods of Grafting and Criteria for the Assessment of Allograft Survival.**—Within 43-120 days after bone marrow transplantation, each recipient underwent bilateral nephrectomy under general halothane anesthesia, followed immediately by transplantation of a kidney obtained from the bone marrow donor. The technique of transplantation has been described previously (37). Complete urinalysis and blood urea nitrogen determinations were performed daily during the 1st month after operation, and at biweekly intervals thereafter. Criteria for the continued survival of each kidney transplant included normal renal function tests and evidence of the ability of the transplanted kidney to maintain the host's life without weight loss, anorexia, and/or vomiting.

The method of skin grafting has been described in an earlier report (35). Briefly, the recipients were anesthetized and the hair of the lateral aspects of the chest was removed. Under sterile precautions, skin surfaces measuring 2 × 2 cm were excised, leaving the intact panniculus carnosus as the graft bed. Skin specimens of the same size were excised from the donors; the subcutaneous fat was removed from each graft by sharp dissection, and the graft was approximated to the recipient bed with interrupted 5-0 nylon sutures. A maximum of four grafts was applied in duplicate to each recipient. Vaseline gauze and compressive gauze dressings were placed on the transplants, and then covered with an adhesive bandage. Dressings were removed on the 7th postoperative day, and the grafts were then examined daily. A graft was considered to have undergone rejection when 75% of the transplanted tissue had become hard, opaque, or necrotic. The diagnosis of rejection was confirmed in each instance by sloughing of the eschar.

For the purposes of this study, each recipient was tested with skin allografts within 230-450 days after bone marrow transplantation. The skin grafts were obtained from the bone marrow donor and from a maximum of three other donors selected on the basis of varying degrees of DL-A compatibility with the recipients.

**RESULTS**

The DL-A genotypes and coefficients of relationship of the donor-recipient pairs presented in this report are outlined in Table I. 11 animals received bone marrow transplants from DL-A-identical littermates. The sires and dams of each pair of animals in this group were completely unrelated in three instances; the coefficients of relationship of the other eight sets of parents varied from $\frac{1}{16}$ to $\frac{1}{28}$. Six dogs received bone marrow transplants from DL-A-identical nonlittermate donors. The donor-recipient coefficients of relationship ranged from $\frac{1}{8}$ to $\frac{1}{8}$. The coefficients of relationship of the parents of each individual donor and recipient in this group ranged from $\frac{1}{64}$ to zero.

The hematological effects of supralethal total body irradiation and bone
marrow transplantation are summarized in Table II. There was a uniform decrease in leukocyte and platelet levels during the first 10–12 days after irradiation, with leukocyte counts in the range of 99–311/mm³, and platelet counts in the range of 4600–63,000/mm³. These values returned to normal levels within 20–110 days after bone marrow transplantation, with leukocyte counts ranging from 6300 to 12,000/mm³, and platelet counts from 107,000 to 257,000/mm³. The serological responses of each recipient to immunization with

DIH vaccine are also summarized in Table II. There was a relative decrease in antibody titers to distemper and infectious hepatitis viruses during the early postirradiation and transplantation period. As noted in Table II, however, such titers generally returned to normal levels within 3–6 months after bone marrow transplantation. At that time, the titers were roughly comparable to antibody levels in the recipients before irradiation.

The results of bone marrow transplantation are outlined in Table III. Bone marrow allografts obtained from prospectively selected DL-A-identical donors are currently surviving for 211–649 days without evidence of GVH disease in 17 consecutive recipients. These include 11 recipients of bone marrow obtained from littermates (315, 364, 424, 440, 531, 531, 584, 605, 625, 645, and 649 days, respectively) and 6 recipients of transplants from nonlittermate donors (211, 279, 280, 418, 479, and 480 days, respectively). Evidence of persisting chimerism
has been obtained at regular intervals in eight informative donor-recipient pairs on the basis of changes in the recipients' erythrocyte group antigens after bone marrow transplantation (recipients 21-60, 21-61, 21-66, 21-73, 21-96, 22-04, 21-97, 22-56). Similar evidence has been obtained in eight pairs by the observation that the recipients' peripheral blood leukocytes had acquired the

### TABLE II

Effects of Supralethal Total Body Irradiation and Bone Marrow Transplantation in Selectively Bred DL-A-Identical Donor-Recipient Pairs of Beagles

| Donor | Recipient | Relation | Leukocyte/platelet levels* of recipients at 7-12 days after irradiation | Serum antibody titers in recipients | Leukocyte/platelet levels after bone marrow transplantation | Serum antibody titers after bone marrow transplantation |
|-------|-----------|----------|------------------------------------------------------------------------|--------------------------------------|------------------------------------------------------------|------------------------------------------------------|
|       |           |          | 7-12 days after | 22-110 days after | Before irradiation | Dis- | Infectious | Dis- | Infectious |
|       |           |          | irradiation  | bone marrow | | temper | hepatitis | temper | hepatitis |
| 21-53 | 21-54     | Littermate | 99/4,666     | 10,800/241,000 | >1/100 | ND | 1/180 | 1/1,250 |
| 21-59 | 21-60     | " " " Littermate | 266/17,500   | 12,000/257,000 | >1/100 | ND | 1/125 | 1/16,000 |
| 21-62 | 21-61     | " " " Littermate | 240/24,250   | 10,300/220,000 | >1/100 | ND | 1/800 | 1/25,000 |
| 21-65 | 21-66     | " " " Littermate | 177/9,600    | 8,800/213,000  | >1/100 | ND | 1/2000 | 1/800 |
| 21-74 | 21-73     | " " " Littermate | 177/17,500   | 12,900/160,000 | >1/100 | ND | 1/1250 | 1/12,500 |
| 21-95 | 21-96     | " " " Littermate | 33/48,000    | 6,300/195,000  | >1/100 | ND | 1/800 | 1/8,000 |
| 22-03 | 22-04     | " " " Littermate | 288/63,000   | 11,600/225,000 | >1/100 | ND | 1/310 | 1/15,800 |
| 22-32 | 22-29     | " " " Littermate | 133/20,500   | 9,800/127,000  | 1/3100 | 1/690 | 1/3100 | 1/310 |
| 22-21 | 22-22     | " " " Littermate | 155/25,000   | 10,500/107,000 | 1/2000 | 1/3,100 | 1/5000 | 1/3,100 |
| 22-43 | 22-40     | " " " Littermate | 211/19,000   | 10,300/137,000 | 1/2000 | 1/6,300 | 1/5000 | 1/8,000 |
| 22-55 | 22-48     | " " " Littermate | 200/30,000   | 8,000/200,000  | 1/2000 | 1/16,000 | 1/80  | 1/12,500 |
| 21-87 | 21-56     | Nonlittermate pairs | 300/32,000   | 14,600/171,000 | 1/500  | 1/3,100 | 1/2000 | 1/3,100 |
| 21-90 | 21-97     | " " " Nonlittermate pairs | 311/36,500   | 12,700/190,000 | 1/310  | 1/3100 | 1/400  | 1/25,000 |
| 22-06 | 22-24     | " " " Nonlittermate pairs | 133/26,000   | 11,200/189,000 | 1/1800 | 1/3,100 | 1/2000 | 1/12,500 |
| 22-52 | 22-56     | " " " Nonlittermate pairs | 277/49,000   | 6,500/160,000  | 1/125  | 1/25,000 | 1/310  | 1/12,500 |
| 22-51 | 22-57     | " " " Nonlittermate pairs | 166/37,500   | 11,400/220,000 | 1/400  | 1/25,000 | 1/100  | 1/25,000 |
| 22-46 | 22-07     | " " " Nonlittermate pairs | 144/15,400   | 10,000/156,000 | 1/310  | 1/4,000 | 1/800  | 1/2,500 |

* Per mm$^3$ of blood.

sex characteristics of their corresponding bone marrow donors (recipients 21-61, 21-96, 22-29, 22-40, 22-48, 22-56, 22-57, 22-07).

As noted in Table IV, renal allografts obtained from the bone marrow donors are currently maintaining normal function in 11 littermate recipients (234, 313, 377, 378, 441, 444, 482, 557, 580, 581, and 586 days, respectively) and in 6 non-littermate recipients (191, 200, 221, 349, 361, and 405 days, respectively). In contrast, renal allografts in 13 untreated littermate recipients under comparable conditions of DL-A compatibility were rejected in 13-38 days (mean survival
time [MST] = 28.3 days). Renal allografts in untreated recipients of DL-A-incompatible transplants survived 11–20 days in eight littermates (MST = 14.8 days) and 10–18 days in 19 nonlittermates (MST = 12.4 days).

The responses to skin allografts observed in the bone marrow chimeras are outlined in Table V. 13 of 14 grafts obtained from the donors of marrow are surviving in a manner indistinguishable from the behavior of skin autografts.

**TABLE III**

Results of Bone Marrow Transplantation in Prospectively Selected Genotypically DL-A-Identical Pairs of Beagles

| Donor Recipient Relation | Survival of bone marrow transplant* days | Swisher erythrocyte groups of Donor | Recipient after transplantation Sex markers of Recipient | Survival of skin grafts |
|--------------------------|------------------------------------------|-------------------------------------|--------------------------------------------------------|------------------------|
| Littermate pairs | >649 | AC | AC | M | M | M |
| 21-53 21-54 | 21-59 21-60 | 645 | C | A | C | M | M | M |
| | 21-62 21-61 | >625 | AC | C | AC | F | M | F |
| | 21-65 21-66 | >605 | C | AC | C | M | M | M |
| | 21-74 21-73 | >584 | C | A | C | M | M | M |
| | 21-95 21-96 | >531 | A | AC | A | M | F | M |
| | 22-03 22-04 | >531 | AC | A | AC | F | F | F |
| | 22-32 22-29 | >440 | C | C | C | F | M | F |
| | 22-21 22-22 | >424 | C | C | C | M | M | M |
| | 22-43 22-40 | >364 | AC | AC | AC | F | M | F |
| | 22-55 22-48 | >315 | AC | AC | AC | F | M | F |
| | 21-87 21-56 | >480 | AC | AC | AC | F | F | F |
| Nonlittermate pairs | >480 | AC | AC | F | F |
| 21-90 21-97 | >479 | AC | A | AC | F | F | F |
| 22-06 22-24 | >418 | C | C | C | M | M | M |
| 22-52 22-56 | >280 | AC | A | AC | F | M | F |
| 22-51 22-57 | >279 | AC | AC | AC | M | F | M |
| 22-46 22-07 | >211 | AC | AC | AC | F | M | F |

* All recipients are surviving uneventfully, with no evidence of secondary disease, as of 15 May 1972.

In seven of eight recipients of littermate bone marrow, the current skin allograft survival is 199, 178, 162, 122, 116, 116, and 110 days, respectively. In six non-littermate recipients, the current survival is 107, 110, 110, 128, 143, and 143 days, respectively. One allograft (recipient 21–60) developed slow progressive rejection changes which were complete by the 84th day after transplantation.

Six recipients of littermate marrow were tested with skin grafts from a DL-A-identical sibling of the bone marrow donor. These grafts were rejected within 20–36 days (MST = 25.8 days). Five recipients of nonlittermate marrow were tested in similar fashion with skin grafts from a DL-A-identical sibling of
the marrow donor. These transplants survived for 27-76 days (MST = 56.2 days).

Nine recipients of bone marrow obtained from littermate donors and six recipients of nonlittermate marrow were tested with one or more skin allografts obtained from DL-A-incompatible donors. The nine dogs rejected 15 DL-A-incompatible skin grafts in 12-26 days (MST = 16.3 days); the second group

### TABLE IV

| Experimental group | Relation between donor and recipient | Kidney allograft survival times (No. of transplants per days listed) | Mean survival time |
|--------------------|--------------------------------------|--------------------------------------------------------------------|-------------------|
| Bone marrow* chimeras | LM* | 1 - - - - (> 254) (> 313) (> 441) (> 537) | - |
|                     | Non-LM | 3 - - - - (> 378) (> 482) (> 581) | - |
| Untreated LM        | 6 - - - - (> 191) (> 349) (> 405) | - |
| Untreated DL-A com- | Non-LM | 12 - - - - (> 200) (> 361) | - |
| patible LM          | 19 - - - - (> 221) | - |

*All renal allografts are surviving with normal function as of the last date of follow-up, 15 May 1972. LM = littermates.

of six dogs rejected 11 DL-A-incompatible skin grafts in 10.5-18 days (MST = 14.5 days).

As noted in Table VI, skin allografts performed in untreated genotypically DL-A-identical pairs of littermates survived for 20-29 days (MST = 25.5 days). This survival was not significantly different from that of DL-A-identical skin allografts in littermate bone marrow chimeras, 22-36 days (MST = 25.8 days) (Table V). It is of interest, however, that reciprocal exchange of skin allografts between DL-A-identical pairs of normal littermates did not regularly result in the same survival times in both animals. In a number of instances, the differences in survival of two such grafts were as great as 5 days.

### DISCUSSION

The results of this study indicate that the use of combined genetic and serological criteria of DL-A compatibility in the prospective selection of DL-A-
**TABLE V**

*Reactivity to Skin Allografts in DL-A-Identical Bone Marrow Chimeras Bearing Donor-Specific Kidney Allografts*

| Bone marrow and kidney donor | Recipient | DL-A genotype | Relationship | Survival time of skin allografts (days) obtained from | Donors with known DL-A incompatibilities |
|-----------------------------|-----------|---------------|--------------|------------------------------------------------------|-----------------------------------------|
|                             |           |               | Bone marrow donor | DL-A-identical sibling of donor | Donor 1 | Donor 2 | Donor 1 | Donor 2 |
| 21-53                       | 21-54     | bkffm/gln     | Littermates     | — | — | 20 | 12.5 | gln | 12.5 | cdn |
| 21-59                       | 21-60     | bkffm/bkhfm   | "             | 84 | 36 | 19 | gln | 19 | cdn | |
| 21-65                       | 21-66     | gln/be        | "             | >162 | — | — | — | — | — | |
| 21-74                       | 21-73     | bkhfm/bkhfm   | "             | >116 | — | 26 | gln | — | — | |
| 21-95                       | 21-96     | gln/gln       | "             | >122 | 32.5 | 16.5 | gln | 14 | cdn | |
| 22-03                       | 22-04     | bkhfm/bkhfm   | "             | — | 22.5 | 18 | gln | — | — | |
| 22-32                       | 22-29     | gln/gln       | "             | >199 | — | 12 | bkhfm | 13 | cdn | |
| 22-21                       | 22-22     | bkcdn/bkhfm   | "             | — | — | 12 | bkcdn | 21 | bkhfm | |
| 22-43                       | 22-40     | bkhfm/gln     | "             | >116 | 22 | 13 | gln | — | — | |
| 22-55                       | 22-48     | bkhfm/bkhfm   | "             | >110 | 22 | 20 | gln | 16.5 | cdn | |
| 21-87                       | 21-56     | bkhfm/bkhfm   | Nonlittermates | >143 | 76 | 16 | gln | 14 | cdn | |
| 21-90                       | 21-97     | bkhfm/bkhfm   | "             | >143 | 27 | 13.5 | gln | 16 | cdn | |
| 22-06                       | 22-24     | gln/gln       | "             | >128 | — | 12 | bkhfm | 11 | bkcdn | |
| 22-52                       | 22-56     | bkhfm/bkhfm   | "             | >110 | 34 | 18 | gln | 16 | cdn | |
| 22-51                       | 22-57     | bkhfm/bkhfm   | "             | >110 | 72 | 18 | gln | 15 | cdn | |
| 22-46                       | 22-47     | gln/gln       | "             | >107 | 72 | 10.5 | bkhfm | — | — | |

* > = allografts continue to survive uneventfully as of the last date of follow-up (15 May 1972).

**TABLE VI**

*Reactivity to Skin Allografts in Untreated DL-A-Identical Littermate Pairs of Beagles*

| Donor | Recipient | DL-A genotype | Skin allograft survival |
|-------|-----------|---------------|-------------------------|
| 14-57 | 14-58     | gln/bkhfm    | 26                      |
| 14-58 | 14-57     | gln/bkhfm    | 26                      |
| 16-68 | 16-69     | bkcdn/gln    | 28                      |
| 16-69 | 16-68     | bkcdn/gln    | 26                      |
| 15-82 | 15-80     | bkhfm/bkhfm  | 25                      |
| 15-80 | 15-82     | bkhfm/bkhfm  | 20                      |
| 16-91 | 16-90     | gln/gln      | 29                      |
| 16-90 | 16-91     | gln/gln      | 25                      |
| 16-89 | 16-88     | gln/gln      | 27                      |
| 16-88 | 16-89     | gln/gln      | 22                      |
| 16-76 | 16-78     | gln/gln      | 26                      |
| 16-78 | 16-76     | gln/gln      | 24                      |
| 16-79 | 16-77     | be/gln       | 26.5                    |
| 16-77 | 16-79     | be/gln       | 26                      |
identical donor-recipient pairs may regularly produce long-term survivals of bone marrow chimeras. A significant array of evidence supports the contention that this effect is specific in nature and is not a reflection of random inbreeding within the Cooperstown Colony. The coefficients of relationship of the bone marrow donors and recipients and of their preceding generation, and the establishment of long-term chimerism with equal ease in littermate and in nonlittermate recipients would appear to militate against such a possibility. In addition, it may be pertinent to note the following: (a) The Cooperstown Colony does not constitute a randomly inbred population; rather it includes a number of selectively bred lines (46), some of which bear the same DL-A genotypes, while others may be phenotypically DL-A compatible but genotypically DL-A different (46); (b) studies in progress at this time indicate that DL-A-incompatible bone marrow transplants regularly fail to survive, even when performed in littermates; (c) genotypically DL-A-identical allografts of other tissues transplanted into untreated Cooperstown Colony recipients are accorded relative prolongations in survival time, but invariably undergo rejection, in littermates as well as in nonlittermates (46); (d) DL-A-incompatible allografts are rejected in an even more rapid manner by both littermates and nonlittermates (46). The relevance of the DL-A marker system to the results observed is highlighted, in addition, by the heterogeneity of the animals studied for other markers present on other chromosomes, such as the Swisher erythrocyte groups, for example.

The long-term survival of 17 consecutive DL-A-identical bone marrow allografts presented in this study differs significantly from earlier studies by Epstein et al. (49), who reported a survival rate of less than 50% at 120 days and less than 30% at 240 days in 17 recipients of littermate marrow allografts selected on the basis of serological criteria of DL-A compatibility (49). These results may reflect the different canine population and serological reagents utilized by Epstein et al. (49) and their use of phenotypic rather than genotypic criteria of compatibility. It must be noted, however, that the data of Epstein et al. (49), as well as the incidence of GVH reactions observed in human recipients of HL-A-identical bone marrow transplants (58, 59), may have been a consequence of donor-recipient incompatibilities for H-antigens which are not as yet detectable by currently available techniques. In this regard, the regularly reproducible bone marrow allograft survivals obtained in this study on the basis of combined genetic and serological criteria of DL-A compatibility in selectively bred lines of beagles may provide an experimental model for the further investigation of such H-antigens and of their role in triggering GVH disease. Rather than localizing such determinants on chromosomes other than those bearing the DL-A region, however, the results of this study raise the alternative possibility that these determinants are genetically linked, i.e., they occur on one major autosomal complex, for which the DL-A genotype serves as an effective marker in the Cooperstown colony. Recent reports (60–64)
indicate that the fate of tissue and of bone marrow allografts in man and in the
mouse may depend upon the products of at least two and possibly more closely
linked genetic systems. Such systems include the serologically detectable HL-A
and H2 systems, as well as products detectable by the mixed leukocyte culture
test (MLC), and a possible cellular immunity locus (61).

The observation that bone marrow transplantation in DL-A-compatible,
MLC-negative littermate dogs (65) and in HL-A-identical, MLC-negative
recipients of human sibling marrow (66) are associated with significant failure
rates, raises the possibility that, in addition to the two postulated DL-A loci,
and to the MLC locus, the proposed main canine histocompatibility complex
may include one or more additional closely linked but genetically separable
determinants, one of which might be termed a “bone marrow transplantation”
locus. Ćudkowicz's (67) recent findings of hybrid resistance genes for bone
marrow transplantation within the analogous histocompatibility complex in
mice would appear to support this possibility. The success rate of bone marrow
transplants observed in the Cooperstown colony may, in this regard, have been
related to the criteria employed for the definition of DL-A genotypic identity
between each littermate or nonlittermate donor-recipient pair selected for
transplantation. Such identity was based upon evidence of the transmission of
the same DL-A genetic material from the same ancestral source (46) for at
least three or four successive generations. The resulting pairs of dogs differed
for other genetic markers, located on other chromosomes. It is possible, how-
ever, that the criteria of selection of donors and recipients for this study identi-
fied, within the Cooperstown colony, those animals sharing components of the
major histocompatibility complex other than DL-A and/or MLC determinants.

The unresponsiveness of the radiation chimeras to kidney and skin allografts
obtained from the bone marrow donors is consonant with the hypothesis of
Main and Prehn (68) that bone marrow transplantation may induce a state of
tolerance to other tissues obtained from the same donor. The immunological
specificity of the induced unresponsiveness is supported by the ability of the
chimeras to reject skin allografts from both DL-A-compatible and DL-A-
incompatible donors. The capacity of the chimeras to muster other forms of
immune responses is attested by their production of normal serum antibody
levels against DIH vaccine within 3-6 months after bone marrow transplanta-
tion. This observation is in agreement with the recent studies of Ochs et al.
(69), who have provided extensive evidence of normal cellular and humoral
immunological function in long-term radiation chimeras.

13 of 14 chimera recipients of skin allografts obtained from the bone marrow
donors have thus far tolerated such transplants as if they were autografts. One
recipient (recipient 21-60) has rejected such an allograft in slow fashion, with
complete destruction of the transplant by the 84th postoperative day. This
chronic response resembles the long-term behavior of skin allografts recently
described in chimeric cattle twins by Stone et al. (70). The fate of the remaining
marrow donor-specific skin allografts is consistent, however, with the thesis that the chimeras are generally rendered tolerant to skin as well as to kidney allografts from the bone marrow donors. This conclusion evidently requires confirmation by a longer period of follow-up of these skin grafts. In this regard, it may be pertinent to note that opinions concerning the ability of bone marrow transplants to induce tolerance to skin are somewhat divided. Some authors suggest that bone marrow transplantation only induces an incomplete or split form of tolerance to other tissues (71-73), and Lance (74) has recently described skin-specific differentiation alloantigens in mice. On the other hand, Main and Prehn (68) and Thomas and Ferrebee (25) have described long-term survivals of skin allografts in radiation chimeras, and Wood et al. (75) have recently observed tolerance to skin allografts in mice treated with antilymphocyte serum and bone marrow cells.

The rejection of skin allografts obtained from other DL-A-identical donors further supports the individual-specific nature of the state of allograft unresponsiveness induced in the recipients. It also highlights the immunological consequences of host reactivity to non-DL-A or "weak" histocompatibility antigens (76-78) present in the skin graft donors but absent in the recipients. This result, taken together with the differences in survival of skin allografts exchanged reciprocally between untreated pairs of DL-A-identical littermates (Table VI), supports the conclusion of Graft et al. (79) that, in the absence of strong donor-recipient incompatibilities, otherwise weak immunogens may exert a cumulative effect upon allograft survival. The results also suggest that the bone marrow donors and recipients reported in this study, while genotypically DL-A identical, may differ by a varying, albeit probably limited number of other H determinants. The long-term survival of bone marrow transplants in the absence of GVH disease in such recipients suggests that relative degrees of accommodation to such non-DL-A histocompatibility barriers may have been developed by the immunologically competent cells transplanted into irradiated recipients. This possibility may provide an explanation for the partial unresponsiveness accorded by radiation chimeras to skin allografts obtained from DL-A-identical littermate siblings of the marrow donors, when such allografts were applied to recipients of bone marrow cells obtained from non-littermate DL-A-identical donors. As noted in Table V, these grafts survived for 27-72 days (MST = 56.2 days), while similar grafts performed in recipients of littermate bone marrow transplants were rejected within 20-36 days (MST = 25.8 days). Such a difference in survival raises the possibility that the individual-specific nature of the unresponsiveness to skin allografts produced in radiation chimeras may have been broadened in nonlittermate marrow recipients to a partial tolerance to skin allografts obtained from DL-A-identical siblings of the bone marrow donors. Such an effect may have been due to the possibility that the bone marrow cells transplanted into nonlittermate recipients were compelled to adapt to a wider spectrum of non-DL-A H-determinants than
was the case in littermate marrow transplants. This possibility is supported by the relationships reported between the strength of histocompatibility barriers and the induction of immunological tolerance in mice (80), and is consistent with the recent observations of Hussey et al. (81) of the occasional success of bone marrow and renal allografts in mongrel dog radiation chimeras.

The precise nature of the mechanisms implicated in the type of allograft unresponsiveness described in this study is not clear at present. It is of interest, however, that blocking antibodies of the Helström type (82) have recently been described in long-term canine bone marrow chimeras (83), and that such antibodies have also been reported in long-term recipients of human renal allografts (84). These observations may be of direct relevance to further studies of mechanisms of allogeneic unresponsiveness in radiation chimeras.

**SUMMARY**

17 Cooperstown beagles of known DL-A genotypes were exposed to supralethal total body irradiation and received a bone marrow allograft from a DL-A-identical donor; 11 littermate and 6 nonlittermate donor-recipient pairs were studied. The recipients are surviving uneventfully for 315, 364, 424, 440, 531, 531, 584, 605, 625, 635, and 649 days in the littermate group and for 211, 279, 280, 306, 479, and 480 days in the nonlittermate group.

The radiation chimeras underwent bilateral nephrectomy and received a kidney allograft obtained from their respective marrow donor within 43–120 days after bone marrow transplantation. The renal allografts are surviving for 191, 200, 221, 234, 313, 349, 361, 377, 378, 405, 441, 444, 482, 557, 580, 581, and 586 days, respectively.

12 of 13 skin allografts obtained from the marrow donor are at present surviving in the recipients for 107, 110, 110, 110, 116, 122, 128, 143, 143, 162, 178, and 199 days, respectively; one graft was rejected at 84 days. In contrast, the radiation chimeras rejected 25 skin allografts obtained from DL-A-incompatible donors within 10.5–21 days (MST = 15.2 days). Skin transplants obtained from DL-A-identical siblings of the bone marrow donors were rejected within 20–36 days (MST = 25.8 days) in recipients of bone marrow cells obtained from littermate donors. Recipients of nonlittermate bone marrow transplants accorded such allografts a prolonged survival time of 27–76 days (MST = 56.2 days).

Prospective selection of genotypically DL-A-identical donor-recipient pairs results in the regularly reproducible long-term survival of bone marrow allografts. The radiation chimeras produced in this manner have developed a donor-specific state of unresponsiveness to kidney and skin allografts. The results are consistent with the existence in the canine species of at least three closely linked genetic systems relevant to transplantation, including DL-A, MLC, and a possible bone marrow transplantation locus.

The authors wish to acknowledge their appreciation of the excellence of the technical assist-
once provided by Mrs. Dorothy St. John and Mr. Barrie Boyle at the Bassett Hospital and Messrs. Arthur Miller, Juan Grullon, and Arturo Quel at New York University, and the valuable professional assistance of Dr. Michiya Matsuyama. We would also like to express our gratitude to Dr. James A. Baker, who provided the distemper-infectious hepatitis vaccine used to immunize the Cooperstown Colony beagles and performed the antibody studies in the recipients.

REFERENCES

1. Lawrence, H. S. 1959. Homograft sensitivity. An expression of the immunological origins and consequences of individuality. *Physiol. Rev.* **39**:811.

2. Lawrence, H. S., and F. T. Rapaport. 1967. Immunological considerations in transplantation. In Proceedings of the 3rd Congress of Nephrology. Karger, Inc., Washington, D.C. 333.

3. Rapaport, F. T., and J. Dausset. 1969. Immunological principles of donor selection for human cardiac transplantation. *Prog. Cardiovasc. Dis.* **12**:119.

4. Gorer, P. A. 1937. The genetic and antigenic basis of tumor transplantation. *J. Pathol. Bacteriol.* **44**:691.

5. Gorer, P. A., and P. O. Goodman. 1956. The cytotoxic activity of iso-antibodies in mice. *Transplant. Bull.* **3**:142.

6. Snell, G. D., P. Smith, and F. Gabrielson. 1953. Analysis of the histocompatibility 2 locus in the mouse. *J. Natl. Cancer Inst.* **14**:457.

7. Snell, G. D., and J. H. Stimpfing. 1966. Genetics of tissue transplantation. In Biology of the Laboratory Mouse. E. L. Green, editor. McGraw-Hill Book Company, New York. 457.

8. Amos, D. B. 1968. Human histocompatibility locus HL-A. *Science (Wash. D.C.).* **159**:559.

9. Palm, J. 1971. Classification of in-bred rat strains for AgB histocompatibility antigens. *Transplant. Proc.* **3**:169.

10. Stark, O., V. Kren, and E. Gunther. 1971. RtH-1 antigens in 39 rat strains and six congenic lines. *Transplant. Proc.* **3**:165.

11. Deweck, A. L., L. Polak, W. Sato, and J. R. Frey. 1971. Determination of histocompatibility antigens by leucocyte typing in outbred guinea pigs and effect of matching on skin graft survival. *Transplant. Proc.* **3**:192.

12. Vaiman, M., C. Renard, P. Lafage, J. Ameteau, and P. Nizza. 1970. Evidence for a histocompatibility system in swine (SL-A). *Transplantation.* **10**:155.

13. Balner, H., W. Vreeswijk, A. van Leeuwen, and J. J. van Rood. 1971. Identification of chimpanzee leucocyte antigens (ChL-A) and their relation to HL-A. *Transplantation.* **11**:309.

14. Balner, H., B. W. Gabb, H. Dersjant, W. Vreeswijk, and J. J. van Rood. 1971. The major histocompatibility locus of Rhesus monkeys (Rh-L-A). *Nature (Lond.).* **230**:177.

15. Brent, L. 1971. Immunological tolerance—1951–71. In Immunological Tolerance to Tissue Antigens. N. W. Nisbet and M. W. Elves, editors. Orthopedic Hospital, Oswestry, England. 1.

16. Billingham, R. E., L. Brent, and P. B. Medawar. 1956. Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance (specific inhibition response). *Philos. Trans. R. Soc. Lond. Ser. B. Biol. Sci.* **239**:357.
17. Kaliss, N. 1958. Immunological enhancement of tumor homografts in mice. Cancer Res. 18:992.
18. Batchelor, J. R. 1963. The mechanisms and significance of immunological enhancement. Guy’s Hosp. Reps. 12:345.
19. Michie, D., and M. F. A. Woodruff. 1956. Induction of specific immunological tolerance in adult mice by sublethal irradiation and injection of donor-type spleen cells in high dosage. Proc. R. Soc. Lond. B Biol. Sci. 156:280.
20. Brent, L., and C. Gowland. 1962. Induction of tolerance of skin homografts in immunologically competent mice. Nature (Lond.). 196:1298.
21. Martinez, C., J. M. Smith, M. Blease, and R. A. Good. 1963. Production of immunological tolerance in mice after repeated injections of disrupted spleen cells. J. Exp. Med. 118:743.
22. Halasz, N. A., L. N. Seifert, H. A. Rosenfield, M. J. Orloff, and H. A. Stier. 1966. The effects of antigen overloading on survival of renal allografts. Proc. Soc. Exp. Biol. Med. 123:24.
23. Van Bekkum, D. W., and M. J. de Vries. 1967. Radiation Chimeras. Academic Press Inc., New York.
24. Ferrebee, J. W., and J. P. Merrill. 1957. Spare parts: a review with a forward look. Surgery. 41:503.
25. Thomas, E. D., and J. W. Ferrebee. 1960. Irradiation and marrow transplantation studies in Cooperstown. Lancet. 1:1289.
26. Mannick, J. A., H. L. Lochte, C. A. Ashley, E. D. Thomas, and J. W. Ferrebee. 1959. A functioning kidney homotransplant in the dog. Surgery. 48:821.
27. Blumenstock, D. A., N. Lempert, K. M. Singer, H. Kasemi, and J. W. Ferrebee. 1970. Late pulmonary function after re-implantation and allotransplantation of the lung in dogs. Transplantation. 10:241.
28. Moore, F. D. 1964. Give and Take, the Development of Tissue Transplantation. W. B. Saunders Company, Philadelphia. 80.
29. Kasakura, S., E. D. Thomas, and J. W. Ferrebee. 1964. Leucocytotoxic isoantibodies in the dog. Transplantation. 2:274.
30. Puza, A., P. Rubinstein, S. Kasakura, S. Vlahovic, and J. W. Ferrebee. 1964. The production of isoantibodies in the dog by immunization with homologous tissue. Transplantation. 2:722.
31. Rubinstein, P., and J. W. Ferrebee. 1964. Efforts to differentiate isohemagglutinins in the dog. Transplantation. 2:734.
32. Cleton, F. J., G. van Es, R. Ponsen, and J. J. van Rood. 1967. Leucocyte antigens in the dog. In Histocompatibility Testing 1967. E. S. Curtoni, P. L. Mattiuiz, and R. M. Tosi, editors. Munksgaard, Copenhagen. 277.
33. Cohen, I., and M. Kozari. 1969. The production of isoantibodies in littermate dogs after allogeneic skin grafting. Transplantation. 7:468.
34. Epstein, R. B., R. Storb, H. Ragde, and F. D. Thomas. 1968. Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation. 6:45.
35. Rubinstein, P., F. Morgado, D. A. Blumenstock, and J. W. Ferrebee. 1968. Isohemagglutinins and histocompatibility in the dog. Transplantation. 6:861.
36. Mollen, N., D. St. John, F. D. Cannon, and J. W. Ferrebee. 1968. Lymphocyte typing in allografted beagles. Transplantation. 6:939.
37. Rapaport, F. T., T. Hanaoka, T. Shimada, F. D. Cannon, and J. W. Ferrebee. 1970. Histocompatibility studies in a closely-bred colony of dogs. I. Influence
of leukocyte group antigens upon renal allograft survival in the unmodified host. *J. Exp. Med.* **131**:881.

38. Rapaport, F. T., A. D. Boyd, F. C. Spencer, R. R. Lower, J. Dausset, F. D. Cannon, and J. W. Ferrebee. 1971. Histocompatibility studies in a closely bred colony of dogs. II. Influence of the DL-A system of canine histocompatibility upon the survival of cardiac allografts. *J. Exp. Med.* **133**:260.

39. Blumenstock, D., E. Wells, C. Sanford, and M. DeGuglio. 1971. Allotransplantation of the lung in beagles and mongrel dogs prospectively typed for lymphocytic antigens. *Transplantation.* **11**:192.

40. Chandler, J. G., H. Villar, S. Lee, R. Williams, J. W. Ferrebee, and M. J. Orloff. 1971. Orthotopic liver transplantation in inbred dogs matched according to lymphocyte types. *Surg. Forum.* **21**:343.

41. Ferrebee, J. W., F. D. Cannon, N. Mollen, and D. St. John. 1970. Beagles for study of histocompatibility and organ transplantation. *Transplantation.* **9**:68.

42. Bos, E., K. Meeter, J. Stibbe, H. M. Vriesendorp, D. L. Westbroek, M. J. deVries, J. Nauta, and J. J. van Rood. 1971. Histocompatibility in orthotopic transplantation in dogs. *Transplant. Proc.* **3**:155.

43. Westbroek, D. L., C. Rothengatter, H. M. Vriesendorp, J. J. van Rood, R. G. J. Willighagen, and M. J. deVries. 1971. Histocompatibility and allografted rejection in canine small bowel transplants. Evidence for the existence of a major histocompatibility locus in the dog. *Transplant. Proc.* **3**:157.

44. Templeton, J. W., and E. D. Thomas. 1971. Evidence for a major histocompatibility locus in the dog. *Transplantation.* **11**:429.

45. Vriesendorp, H. M., E. Rothengatter, E. Bos, D. L. Westbroek, and J. J. van Rood. 1971. The production and evaluation of dog allolymphocytotoxins for donor selection in transplantation experiments. *Transplantation.* **11**:440.

46. Dausset, J., F. T. Rapaport, F. D. Cannon, and J. W. Ferrebee. 1971. Histocompatibility studies in a closely bred colony of dogs. III. Genetic definition of the DL-A system of canine histocompatibility, with particular reference to the comparative immunogenicity of the major transplantable organs. *J. Exp. Med.* **134**:1222.

47. Rapaport, F. T., F. D. Cannon, D. A. Blumenstock, K. Watanabe, and J. W. Ferrebee. 1971. Long term survival of bone marrow and kidney allografts in irradiated DL-A identical dogs. *Transplant. Proc.* **3**:1337.

48. Rapaport, F. T., F. D. Cannon, D. A. Blumenstock, K. Watanabe, and J. W. Ferrebee. 1972. Induction of unresponsiveness to canine renal allografts by total body irradiation and bone marrow transplantation. *Nat. New Biol.* **235**:190.

49. Epstein, R. B., R. Storb, and E. D. Thomas. 1971. Relation of canine histocompatibility testing to marrow grafting. *Transplant. Proc.* **3**:161.

50. Swisher, S. N., and L. E. Young. 1961. The blood grouping systems of dogs. *Physiol. Rev.* **41**:495.

51. Hager, E. B., J. L. Mannick, E. D. Thomas, and J. W. Ferrebee. 1961. Dogs that survive "lethal" exposures to radiation. *Radiation Res.* **14**:192.

52. Thomas, E. D., J. A. Collins, E. C. Herman, Jr., and J. W. Ferrebee. 1962. Marrow transplants in lethally irradiated dogs given methotrexate. *Blood.* **19**:217.

53. Thomas, E. D., G. L. Plain, T. C. Graham, and J. W. Ferrebee. 1964. Long-
HISTOCOMPATIBILITY STUDIES IN DOGS. IV

term survival of lethally irradiated dogs given homografts of bone marrow.

Blood. 23:488.

54. Epstein, R. B., J. Bryant, and E. D. Thomas. 1967. Cytogenetic demonstration of permanent tolerance in adult outbred dogs. Transplantation. 5:267.

55. Burgher, J. A., J. A. Baker, S. Sarker, V. Marshall, and J. H. Gillespie. 1958. Evaluation of a combined vaccine consisting of modified canine distemper virus and modified infectious canine hepatitis virus for simultaneous immunization of dogs. Cornell Vet. 48:214.

56. Gillespie, J. H., J. A. Baker, J. Burgher, D. Robson, and B. Gilman. 1958. The immune response of dogs to distemper virus. Cornell Vet. 48:103.

57. Carmichael, L. E., D. S. Robson, and F. D. Barnes. 1962. Transfer and decline of maternal infectious canine hepatitis antibody in puppies. Proc. Soc. Exp. Biol. Med. 109:677.

58. Graw, R. G., G. P. Herzig, G. N. Rogentine, R. A. Yankee, B. Leventhal, J. Whang-Peng, R. H. Halterman, G. Kruger, C. Berard, and R. S. Henderson. 1970. Graft-versus-host reaction complicating HL-A matched bone marrow transplantation. Lancet. 2:1053.

59. Congdon, C. C. 1971. Bone marrow transplantation. Science (Wash. D.C.). 171:1116.

60. Amos, D. B., and F. H. Bach. 1968. Phenotypic expressions of the major histocompatibility locus in man (HL-A): leukocyte antigens and mixed leukocyte culture reactivity. J. Exp. Med. 128:523.

61. Yunis, E. J., and D. B. Amos. 1971. Three closely linked genetic systems relevant to transplantation. Proc. Natl. Acad. Sci. U.S.A. 68:3031.

62. Bach, F. H., and M. Segall. 1972. Genetics of the mixed leucocyte culture response. A re-examination. Transplant. Proc. 4:205.

63. Eijsvoogel, V. P., L. Koning, L. De Groot-Kooy, L. Huismans, J. J. van Rood, A. van Leeuwen, and E. D. Du Toit. 1972. Mixed lymphocyte culture and HL-A. Transplant. Proc. 4:199.

64. Sasportes, M., A. Lebrun, F. T. Rapaport, and J. Dausset. 1972. Serologically undetectable immune responses in transplantation. Transplant Proc. 4:219.

65. Storb, R., R. H. Rudolph, and E. D. Thomas. 1971. Marrow grafts between canine siblings matched by serotyping and mixed leucocyte culture. J. Clin. Invest. 50:1272.

66. Budkley, R. H. 1971. Reconstitution: grafting of bone marrow and thymus. In Progress in Immunology. D. B. Amos, editor. Academic Press Inc., New York. 1061.

67. Cudkowicz, G. 1971. Genetic control of bone marrow graft rejection. I. Determinant-specific difference of reactivity in two pairs of inbred mouse strains. J. Exp. Med. 134:281.

68. Main, J. M., and R. T. Prehn. 1955. Successful homografts after the administration of high dosage x-irradiation and homologous bone marrow. J. Natl. Cancer Inst. 15:1023.

69. Ochs, H. D., R. Storb, T. C. Graham, R. H. Rudolph, H. J. Kolb, R. A. Shiurba, and E. D. Thomas. 1971. Immune status of long-term canine irradiation chimeras. Blood. 38:787.

70. Stone, W. H., R. G. Cragle, D. F. Johnson, J. A. Bacon, S. Brendel, and N. Korda.
1971. Long-term observations of skin grafts between chimeric cattle twins. *Transplantation.* 12:421.
71. Argyris, B. F. 1962. Loss of acquired tolerance to skin homografts in mice. *J. Plast. Reconstr. Surg.* 30:530.
72. Warner, N. L., L. A. Herzenberg, L. J. Cole, and W. E. Davis. 1965. Dissociation of skin homograft tolerance and donor-type gamma globulin synthesis in allogeneic mouse radiation chimeras. *Nature (Lond.)* 206:1077.
73. Boyse, E. A., and L. J. Old. 1968. Loss of skin allograft tolerance by chimeras. *Transplantation.* 6:619.
74. Lance, E. M. 1972. The application of in vitro tests to the study of differentiation alloantigens. *Transplant. Proc.* In press.
75. Wood, M. L., J. J. Gozzo, G. Heppner, and A. P. Monaco. 1972. Cell-mediated immunity and serum blocking factor in tolerance produced in mice with antilymphocyte serum and bone marrow cell infusion. *Transplant. Proc.* 4:354.
76. Counce, S., P. Smith, R. Barth, and G. D. Snell. 1956. Strong and weak histocompatibility gene differences in mice and their role in the rejection of homografts of tumors and skin. *Ann. Surg.* 144:198.
77. McKhann, C. F., and J. H. Berrian. 1961. Immunologic properties of weak histocompatibility genes. *J. Immunol.* 86:170.
78. McKhann, C. F. 1962. Weak histocompatibility genes. The effect of dose and pre-treatment of immunizing cells. *J. Immunol.* 88:500.
79. Graff, R. J., W. K. Silvers, R. E. Billingham, W. H. Hildemann, and G. D. Snell. 1966. The cumulative effect of histocompatibility antigens. *Transplantation.* 4:605.
80. Lengerova, A., and V. Matousek. 1966. Strength of histocompatibility barriers and induction of immunological tolerance. *Folia Biol. (Praha).* 12:319.
81. Hussey, J. L., A. Daouk, S. Elhabashi, and W. A. Kisken. 1971. Renal allograft survival in bone marrow chimeras. *Surg. Forum.* 22:233.
82. Hellström, K. E., and I. Hellström. 1970. Immunological enhancement as studied by cell culture techniques. *Annu. Rev. Microbiol.* 24:373.
83. Hellström, I., K. E. Hellström, R. Storb, and E. D. Thomas. 1970. Colony inhibition of fibroblasts from chimeric dogs mediated by the dogs' own lymphocytes and specifically abrogated by their serum. *Proc. Natl. Acad. Sci. U.S.A.* 66:65.
84. Quadracci, L. J., I. E. Hellström, G. E. Striker, T. L. Marchioro, and K. E. Hellström. 1970. Immune mechanisms in human recipients of renal allografts. *Cell. Immunol.* 1:561.